{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,9,10]],"date-time":"2024-09-10T00:15:09Z","timestamp":1725927309439},"reference-count":31,"publisher":"Galenos Yayinevi","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Tjh"],"DOI":"10.4274\/tjh.galenos.2024.2024.0011","type":"journal-article","created":{"date-parts":[[2024,5,27]],"date-time":"2024-05-27T10:23:37Z","timestamp":1716805417000},"page":"0-0","source":"Crossref","is-referenced-by-count":0,"title":["Myeloproliferative Neoplasm Symptom Assessment Total Symptom Score (MPN-SAF TSS) in Chronic Myeloproliferative Neoplasms, Related with Genetic Burden, and Thrombosis"],"prefix":"10.4274","author":[{"given":"Elif","family":"\u00dcmit","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mehmet","family":"Baysal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hakk\u0131 Onur","family":"K\u0131rk\u0131zlar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ahmet Muzaffer","family":"Demir","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"2811","published-online":{"date-parts":[[2024,5,27]]},"reference":[{"key":"ref0","doi-asserted-by":"publisher","first-page":"2708","DOI":"10.1200\/JCO.2017.72.6745","article-title":"Practical implications of the 2016 Revision of the World Health Organization Classification of Lymphoid and Myeloid Neoplasms and Acute Leukemia","volume":"35","author":"Leonard","year":"2017","unstructured":"1. Leonard JP, Martin P, Roboz GJ. Practical implications of the 2016 Revision of the World Health Organization Classification of Lymphoid and Myeloid Neoplasms and Acute Leukemia. J Clin Oncol. 2017;35:2708-2715.","journal-title":"J Clin Oncol"},{"key":"ref1","doi-asserted-by":"publisher","first-page":"2475","DOI":"10.1182\/blood-2017-06-782037","article-title":"Myeloproliferative neoplasms: from origins to outcomes","volume":"130","author":"Nangalia","year":"2017","unstructured":"2. Nangalia J, Green AR. Myeloproliferative neoplasms: from origins to outcomes. Blood. 2017;130:2475-2483.","journal-title":"Blood"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"961","DOI":"10.1080\/17474086.2017.1380515","article-title":"Mutations in myeloproliferative neoplasms - their significance and clinical use","volume":"10","author":"Schischlik","year":"2017","unstructured":"3. Schischlik F, Kralovics R. Mutations in myeloproliferative neoplasms - their significance and clinical use. Expert Rev Hematol. 2017;10:961-973.","journal-title":"Expert Rev Hematol"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1016\/j.hoc.2020.12.002","article-title":"Genetics of myeloproliferative neoplasms","volume":"35","author":"Szybinski","year":"2021","unstructured":"4. Szybinski J, Meyer SC. Genetics of myeloproliferative neoplasms. Hematol Oncol Clin North Am. 2021;35:217-236.","journal-title":"Hematol Oncol Clin North Am"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1016\/j.hoc.2020.12.001","article-title":"Overview of myeloproliferative neoplasms: history, pathogenesis, diagnostic criteria, and complications","volume":"35","author":"Tremblay","year":"2021","unstructured":"5. Tremblay D, Yacoub A, Hoffman R. Overview of myeloproliferative neoplasms: history, pathogenesis, diagnostic criteria, and complications. Hematol Oncol Clin North Am. 2021;35:159-176.","journal-title":"Hematol Oncol Clin North Am"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1016\/j.hoc.2020.12.006","article-title":"Quality of life in myeloproliferative neoplasms: symptoms and management implications","volume":"35","author":"Mesa","year":"2021","unstructured":"6. Mesa R, Palmer J, Eckert R, Huberty J. Quality of life in myeloproliferative neoplasms: symptoms and management implications. Hematol Oncol Clin North Am. 2021;35:375-390.","journal-title":"Hematol Oncol Clin North Am"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"284706","DOI":"10.1155\/2015\/284706","article-title":"Impact of inflammation on myeloproliferative neoplasm symptom development","volume":"2015","author":"Geyer","year":"2015","unstructured":"7. Geyer HL, Dueck AC, Scherber RM, Mesa RA. Impact of inflammation on myeloproliferative neoplasm symptom development. Mediators Inflamm. 2015;2015:284706.","journal-title":"Mediators Inflamm"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"1356","DOI":"10.1200\/JCO.2010.32.9490","article-title":"Circulating interleukin (IL)-8, IL-2R, IL-12, and IL-15 levels are independently prognostic in primary myelofibrosis: a comprehensive cytokine profiling study","volume":"29","author":"Tefferi","year":"2011","unstructured":"8. Tefferi A, Vaidya R, Caramazza D, Finke C, Lasho T, Pardanani A. Circulating interleukin (IL)-8, IL-2R, IL-12, and IL-15 levels are independently prognostic in primary myelofibrosis: a comprehensive cytokine profiling study. J Clin Oncol. 2011;29:1356-1363.","journal-title":"J Clin Oncol"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"1003","DOI":"10.1002\/ajh.23295","article-title":"Plasma cytokines in polycythemia vera: phenotypic correlates, prognostic relevance, and comparison with myelofibrosis","volume":"87","author":"Vaidya","year":"2012","unstructured":"9. Vaidya R, Gangat N, Jimma T, Finke CM, Lasho TL, Pardanani A, Tefferi A. Plasma cytokines in polycythemia vera: phenotypic correlates, prognostic relevance, and comparison with myelofibrosis. Am J Hematol. 2012;87:1003-1005.","journal-title":"Am J Hematol"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1016\/j.exphem.2014.01.006","article-title":"Cytokine profiles in polycythemia vera and essential thrombocythemia patients: clinical implications","volume":"42","author":"Pourcelot","year":"2014","unstructured":"10. Pourcelot E, Trocme C, Mondet J, Bailly S, Toussaint B, Mossuz P. Cytokine profiles in polycythemia vera and essential thrombocythemia patients: clinical implications. Exp Hematol. 2014;42:360-368.","journal-title":"Exp Hematol"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1182\/blood-2011-01-328955","article-title":"The Myeloproliferative Neoplasm Symptom Assessment Form (MPN-SAF): international prospective validation and reliability trial in 402 patients","volume":"118","author":"Scherber","year":"2011","unstructured":"11. Scherber R, Dueck AC, Johansson P, Barbui T, Barosi G, Vannucchi AM, Passamonti F, Andreasson B, Ferarri ML, Rambaldi A, Samuelsson J, Birgegard G, Tefferi A, Harrison CN, Radia D, Mesa RA. The Myeloproliferative Neoplasm Symptom Assessment Form (MPN-SAF): international prospective validation and reliability trial in 402 patients. Blood. 2011;118:401-408.","journal-title":"Blood"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"4098","DOI":"10.1200\/JCO.2012.42.3863","article-title":"Myeloproliferative neoplasm (MPN) symptom assessment form total symptom score: prospective international assessment of an abbreviated symptom burden scoring system among patients with MPNs","volume":"30","author":"Emanuel","year":"2012","unstructured":"12. Emanuel RM, Dueck AC, Geyer HL, Kiladjian JJ, Slot S, Zweegman S, te Boekhorst PA, Commandeur S, Schouten HC, Sackmann F, Kerguelen Fuentes A, Hern\u00e1ndez-Maraver D, Pahl HL, Griesshammer M, Stegelmann F, Doehner K, Lehmann T, Bonatz K, Reiter A, Boyer F, Etienne G, Ianotto JC, Ranta D, Roy L, Cahn JY, Harrison CN, Radia D, Muxi P, Maldonado N, Besses C, Cervantes F, Johansson PL, Barbui T, Barosi G, Vannucchi AM, Passamonti F, Andreasson B, Ferrari ML, Rambaldi A, Samuelsson J, Birgegard G, Tefferi A, Mesa RA. Myeloproliferative neoplasm (MPN) symptom assessment form total symptom score: prospective international assessment of an abbreviated symptom burden scoring system among patients with MPNs. J Clin Oncol. 2012;30:4098-4103.","journal-title":"J Clin Oncol"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"1145","DOI":"10.1182\/blood.2020008043","article-title":"Clinical insights into the origins of thrombosis in myeloproliferative neoplasms","volume":"137","author":"Moliterno","year":"2021","unstructured":"13. Moliterno AR, Ginzburg YZ, Hoffman R. Clinical insights into the origins of thrombosis in myeloproliferative neoplasms. Blood. 2021;137:1145-1153.","journal-title":"Blood"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"174","DOI":"10.4274\/tjh.galenos.2023.2023.0169","article-title":"Clinical impact of JAK2V617F allele burden in Philadelphia-negative myeloproliferative neoplasms","volume":"40","author":"Y\u00f6nal-Hindilerden \u0130","year":"2023","unstructured":"14. Y\u00f6nal-Hindilerden \u0130, \u015eahin E, Hindilerden F, Da\u011flar-Aday A, Nal\u00e7ac\u0131 M. Clinical impact of JAK2V617F allele burden in Philadelphia-negative myeloproliferative neoplasms. Turk J Hematol. 2023;40:174-182.","journal-title":"Turk J Hematol"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"26","DOI":"10.4274\/tjh.galenos.2024.2023.0430","article-title":"Impact of CALR and JAK2V617F mutations on clinical course and disease outcomes in essential thrombocythemia: a multicenter retrospective study in Turkish patients","volume":"41","author":"Narl\u0131 \u00d6zdemir","year":"2024","unstructured":"15. Narl\u0131 \u00d6zdemir Z, \u0130pek Y, Pat\u0131r P, Ermi\u015f G, \u00c7ift\u00e7iler R, \u00d6zmen D, Baysal M, G\u00fcrsoy V, Y\u0131ld\u0131zhan E, G\u00fcven S, Ercan T, Elibol T, Mersin S, Gen\u00e7 E, Davulcu EA, Karaku\u015f V, Erkut N, G\u00fcne\u015f G, Diz K\u00fc\u00e7\u00fckkaya R, E\u015fkazan AE. Impact of CALR and JAK2V617F mutations on clinical course and disease outcomes in essential thrombocythemia: a multicenter retrospective study in Turkish patients. Turk J Hematol. 2024;41:26-36.","journal-title":"Turk J Hematol"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1182\/asheducation.V2012.1.571.3798557","article-title":"Thrombotic disease in the myeloproliferative neoplasms","volume":"2012","author":"Falanga","year":"2012","unstructured":"16. Falanga A, Marchetti M. Thrombotic disease in the myeloproliferative neoplasms. Hematology Am Soc Hematol Educ Program. 2012;2012:571-581.","journal-title":"Hematology Am Soc Hematol Educ Program"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1002\/cncr.22365","article-title":"The burden of fatigue and quality of life in myeloproliferative disorders (MPDs): an international Internet-based survey of 1179 MPD patients","volume":"109","author":"Mesa","year":"2007","unstructured":"17. Mesa RA, Niblack J, Wadleigh M, Verstovsek S, Camoriano J, Barnes S, Tan AD, Atherton PJ, Sloan JA, Tefferi A. The burden of fatigue and quality of life in myeloproliferative disorders (MPDs): an international Internet-based survey of 1179 MPD patients. Cancer. 2007;109:68-76.","journal-title":"Cancer"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"325","DOI":"10.12804\/revistas.urosario.edu.co\/revsalud\/a.6116","article-title":"Validation of the Abbreviated Symptom Scale for Patients with Myeloproliferative Neoplasm (MPN-SAF-TSS): evaluation for Colombian patients","volume":"15","author":"Lozano","year":"2017","unstructured":"18. Lozano T, Wiesner C, Mesa R, Robyn ME, Sua\u0301rez M, Salguero E. Validation of the Abbreviated Symptom Scale for Patients with Myeloproliferative Neoplasm (MPN-SAF-TSS): evaluation for Colombian patients. Rev Cienc Salud. 2017;15:325-334.","journal-title":"Rev Cienc Salud"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"207","DOI":"10.14740\/jh914","article-title":"Validation of a modified version of the Myeloproliferative Neoplasm Symptom Assessment Form Total Symptom Score","volume":"10","author":"Langlais","year":"2021","unstructured":"19. Langlais BT, Mazza GL, Kosiorek HE, Palmer J, Mesa R, Dueck AC. Validation of a modified version of the Myeloproliferative Neoplasm Symptom Assessment Form Total Symptom Score. J Hematol. 2021;10:207-211.","journal-title":"J Hematol"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1016\/j.htct.2020.10.966","article-title":"Myeloproliferative Neoplasm Symptom Assessment Form - Total Symptom Score (MPN-SAF TSS) questionnaire: translation, cultural adaptation and validation to Brazilian Portuguese","volume":"44","author":"Guaran\u00e1","year":"2022","unstructured":"20. Guaran\u00e1 M, Soares A, Daumas A, Biasoli I, Solza C. Myeloproliferative Neoplasm Symptom Assessment Form - Total Symptom Score (MPN-SAF TSS) questionnaire: translation, cultural adaptation and validation to Brazilian Portuguese. Hematol Transfus Cell Ther. 2022;44:321-327.","journal-title":"Hematol Transfus Cell Ther"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"1285","DOI":"10.1200\/JCO.2012.44.4489","article-title":"Effect of ruxolitinib therapy on myelofibrosis-related symptoms and other patient-reported outcomes in COMFORT-I: a randomized, double-blind, placebo-controlled trial","volume":"31","author":"Mesa","year":"2013","unstructured":"21. Mesa RA, Gotlib J, Gupta V, Catalano JV, Deininger MW, Shields AL, Miller CB, Silver RT, Talpaz M, Winton EF, Harvey JH, Hare T, Erickson-Viitanen S, Sun W, Sandor V, Levy RS, Kantarjian HM, Verstovsek S. Effect of ruxolitinib therapy on myelofibrosis-related symptoms and other patient-reported outcomes in COMFORT-I: a randomized, double-blind, placebo-controlled trial. J Clin Oncol. 2013;31:1285-1292.","journal-title":"J Clin Oncol"},{"key":"ref21","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1111\/j.1524-4733.2005.04054.x","article-title":"Principles of Good Practice for the Translation and Cultural Adaptation Process for Patient-Reported Outcomes (PRO) Measures: report of the ISPOR Task Force for Translation and Cultural Adaptation","volume":"8","author":"Wild","year":"2005","unstructured":"22. Wild D, Grove A, Martin M, Eremenco S, McElroy S, Verjee-Lorenz A, Erikson P; ISPOR Task Force for Translation and Cultural Adaptation. Principles of Good Practice for the Translation and Cultural Adaptation Process for Patient-Reported Outcomes (PRO) Measures: report of the ISPOR Task Force for Translation and Cultural Adaptation. Value Health. 2005;8:94-104.","journal-title":"Value Health"},{"doi-asserted-by":"publisher","unstructured":"23. Uyanik MS, Baysal M, Pamuk GE, Maden M, Akker M, Umit EG, Demir M, Aydogdu E. Is JAK2V617F mutation the only factor for thrombosis in Philadelphia-negative chronic myeloproliferative neoplasms? Indian J Hematol Blood Transfus. 2016;32:262-267.","key":"ref22","DOI":"10.1007\/s12288-015-0578-2"},{"key":"ref23","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1007\/s12288-016-0685-8","article-title":"The impact of mean platelet volume (MPV) and JAK-2 mutation on thrombosis in chronic myeloproliferative diseases","volume":"33","author":"Ayer","year":"2017","unstructured":"24. Ayer M, Menken \u0130, Yamak M, Ayer FA, K\u0131rk\u0131zlar O, Burak Aktu\u011flu M. The impact of mean platelet volume (MPV) and JAK-2 mutation on thrombosis in chronic myeloproliferative diseases. Indian J Hematol Blood Transfus. 2017;33:181-187.","journal-title":"Indian J Hematol Blood Transfus"},{"key":"ref24","doi-asserted-by":"publisher","first-page":"272","DOI":"10.1016\/j.thromres.2014.11.006","article-title":"The JAK2 V617F mutational status and allele burden may be related with the risk of venous thromboembolic events in patients with Philadelphia-negative myeloproliferative neoplasms","volume":"135","author":"Borowczyk","year":"2015","unstructured":"25. Borowczyk M, Wojtaszewska M, Lewandowski K, Gil L, Lewandowska M, Lehmann-Kopyd\u0142owska A, Kroll-Balcerzak R, Balcerzak A, Iwo\u0142a M, Michalak M, Komarnicki M. The JAK2 V617F mutational status and allele burden may be related with the risk of venous thromboembolic events in patients with Philadelphia-negative myeloproliferative neoplasms. Thrombosis Res. 2015;135:272-280.","journal-title":"Thrombosis Res"},{"key":"ref25","doi-asserted-by":"publisher","first-page":"1952","DOI":"10.1038\/sj.leu.2404854","article-title":"Prospective identification of high-risk polycythemia vera patients based on JAK2V617F allele burden","volume":"21","author":"AM","year":"2007","unstructured":"26. Vannucchi AM, Antonioli E, Guglielmelli P, Longo G, Pancrazzi A, Ponziani V, Bogani C, Ferrini PR, Rambaldi A, Guerini V, Bosi A, Barbui T; MPD Research Consortium. Prospective identification of high-risk polycythemia vera patients based on JAK2V617F allele burden. Leukemia. 2007;21:1952-1959.","journal-title":"Leukemia"},{"key":"ref26","doi-asserted-by":"publisher","first-page":"127","DOI":"10.4103\/sajc.sajc_161_18","article-title":"Influence of JAK2V617F allele burden on clinical phenotype of polycythemia vera patients: a study from India","volume":"8","author":"Sazawal","year":"2019","unstructured":"27. Sazawal S, Singh K, Chhikara S, Chaubey R, Mahapatra M, Saxena R. Influence of JAK2V617F allele burden on clinical phenotype of polycythemia vera patients: a study from India. South Asian J Cancer. 2019;8:127-129.","journal-title":"South Asian J Cancer"},{"key":"ref27","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1007\/s11899-017-0399-5","article-title":"Approach to MPN symptom assessment","volume":"12","author":"Geyer","year":"2017","unstructured":"28. Geyer H, Mesa RA. Approach to MPN symptom assessment. Curr Hematol Malig Rep. 2017;12:381-388.","journal-title":"Curr Hematol Malig Rep"},{"key":"ref28","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1016\/j.leukres.2017.10.002","article-title":"Symptom burden profile in myelofibrosis patients with thrombocytopenia: Lessons and unmet needs","volume":"63","author":"Scotch","year":"2017","unstructured":"29. Scotch AH, Kosiorek H, Scherber R, Dueck AC, Slot S, Zweegman S, Boekhorst PAWT, Commandeur S, Schouten H, Sackmann F, Fuentes AK, Hern\u00e1ndez-Maraver D, Pahl HL, Griesshammer M, Stegelmann F, D\u00f6hner K, Lehmann T, Bonatz K, Reiter A, Boyer F, Etienne G, Ianotto JC, Ranta D, Roy L, Cahn JY, Harrison CN, Radia D, Muxi P, Maldonado N, Besses C, Cervantes F, Johansson PL, Barbui T, Barosi G, Vannucchi AM, Paoli C, Passamonti F, Andreasson B, Ferrari ML, Rambaldi A, Samuelsson J, Birgegard G, Xiao Z, Xu Z, Zhang Y, Sun X, Xu J, Kiladjian JJ, Zhang P, Gale RP, Mesa RA, Geyer HL. Symptom burden profile in myelofibrosis patients with thrombocytopenia: Lessons and unmet needs. Leuk Res. 2017;63:34-40.","journal-title":"Leuk Res"},{"doi-asserted-by":"publisher","unstructured":"30. Mesa RA, Jamieson C, Bhatia R, Deininger MW, Fletcher CD, Gerds AT, Gojo I, Gotlib J, Gundabolu K, Hobbs G, McMahon B, Mohan SR, Oh S, Padron E, Papadantonakis N, Pancari P, Podoltsev N, Rampal R, Ranheim E, Reddy V, Rein LAM, Scott B, Snyder DS, Stein BL, Talpaz M, Verstovsek S, Wadleigh M, Wang ES, Bergman MA, Gregory KM, Sundar H. NCCN Guidelines Insights: Myeloproliferative Neoplasms, Version 2.2018. J Natl Compr Canc Netw. 2017;15:1193-1207.","key":"ref29","DOI":"10.6004\/jnccn.2017.0157"},{"key":"ref30","doi-asserted-by":"publisher","first-page":"844","DOI":"10.1080\/10428194.2017.1365852","article-title":"MPN10 score and survival of molecularly annotated myeloproliferative neoplasm patients","volume":"59","author":"ElNahass","year":"2018","unstructured":"31. ElNahass YH, Mahmoud HK, Mattar MM, Fahmy OA, Samra MA, Abdelfattah RM, ElRefaey FA, Fahmy HM, Fathy GM, Abdulgawad A, AbdelKader M, Elleithy HN, Gamil M, Talaat M, Nader HA, ElMetnawy WH. MPN10 score and survival of molecularly annotated myeloproliferative neoplasm patients. Leuk Lymphoma. 2018;59:844-854.","journal-title":"Leuk Lymphoma"}],"container-title":["Turkish Journal of Hematology"],"original-title":[],"deposited":{"date-parts":[[2024,9,9]],"date-time":"2024-09-09T07:24:07Z","timestamp":1725866647000},"score":1,"resource":{"primary":{"URL":"https:\/\/jag.journalagent.com\/z4\/download_fulltext.asp?pdir=tjh&plng=eng&un=TJH-15975"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5,27]]},"references-count":31,"URL":"https:\/\/doi.org\/10.4274\/tjh.galenos.2024.2024.0011","relation":{},"ISSN":["1300-7777","1308-5263"],"issn-type":[{"type":"print","value":"1300-7777"},{"type":"electronic","value":"1308-5263"}],"subject":[],"published":{"date-parts":[[2024,5,27]]}}}